Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fibrillation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    436 result(s) found for: Fibrillation. Displaying page 9 of 22.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2006-004761-34 Sponsor Protocol Number: 150-CL-012 Start Date*: 2007-04-19
    Sponsor Name:Astellas US Pharma US Inc.(APUS)
    Full Title: A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability and Pharmacodynamics of YM150 in Subjects with Non-Valvular Atrial Fibrillation.
    Medical condition: Prevention of stroke on patients with Non-Valvular Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    8.1 10049165 Cerebrovascular accident prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000307-17 Sponsor Protocol Number: 69HCL16_0743 Start Date*: 2018-07-19
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Microcirculatory and Macrocirculatory Effects of Landiolol on Postoperative Atrial Fibrillation: a Randomized Study. MMELPOAF study.
    Medical condition: Postoperative Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016077-14 Sponsor Protocol Number: RALF1 Start Date*: 2010-11-11
    Sponsor Name:Mika Lehto
    Full Title: Role of ALiskiren, a direct renin inhibitor, in preventing atrial Fibrillation in patients with a pacemaker; RALF Eteisvärinäkuorman määritys sydämentahdistimella aliskireenihoidossa
    Medical condition: Patients who have a pacemaker due to sinus node disease and paroxysmal atrial fibrillation.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067824 Prophylaxis against atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-024552-28 Sponsor Protocol Number: 1 Start Date*: 2012-12-03
    Sponsor Name:Oxford Radcliffe Hospitals NHS Trust
    Full Title: BRUISE CONTROL : BRidge or continUe coumadIn for device SurgEry randomized CONTROLled Trial
    Medical condition: The primary study endpoint is the risk of haematoma formation with cardiac device operation using either warfarin anticoagulation or heparin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000112-33 Sponsor Protocol Number: NL47761.041.14 Start Date*: 2014-09-01
    Sponsor Name:University Medical Center Utrecht
    Full Title: Apixaban versus antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation. A randomised phase II clinical trial.
    Medical condition: The prevention of ischaemic stroke in patients with atrial fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-003997-33 Sponsor Protocol Number: NOAH-AFNET6 Start Date*: 2016-11-18
    Sponsor Name:Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork]
    Full Title: Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes
    Medical condition: Atrial fibrillation (AF) is one cause of stroke. Stroke rate is increased in patients with atrial high rate episodes (AHRE, an early stage of AF) as well, even if stroke rates are lower when compa...
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004849 10003656 Atrial arrhythmia LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) BG (Completed) SE (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) PT (Prematurely Ended) GR (Completed) DK (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-005072-40 Sponsor Protocol Number: 1235-SR-202-AF Start Date*: 2007-03-12
    Sponsor Name:Cardiome Pharma Corp.
    Full Title: Vernakalant (oral) Prevention of Atrial Fbrillation Recurrence Post-Conversion Study
    Medical condition: Atrial fibrillation is the most common arrhythmia encountered in clinical practice. Atrial fibrillation is usually associated with age and general physical condition, rather than with a specific ca...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066664 Recurrent symptomatic atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SE (Completed) DE (Completed) DK (Completed) SK (Completed) HU (Completed) EE (Completed) BG (Completed) LT (Completed) ES (Completed) CZ (Completed) PT (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000236-34 Sponsor Protocol Number: ELAN Start Date*: 2019-02-26
    Sponsor Name:Inselspital (University Hospital) Bern
    Full Title: Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): an international, multicentre, randomised-controlled, two-arm, assessor...
    Medical condition: Recurrent strokes in patients with atrial fibrillation who suffered an ischaemic stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) FI (Completed) BE (Completed) DE (Completed) SK (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002147-91 Sponsor Protocol Number: CV185-030 Start Date*: 2007-05-14
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase 3, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Nonvalv...
    Medical condition: ARRHYTHMIA; THROMBOSIS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003658 Atrial fibrillation LLT
    9.1 10057613 Thromboembolic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed) BE (Completed) FI (Completed) ES (Completed) DK (Completed) HU (Completed) AT (Completed) CZ (Completed) FR (Completed) DE (Completed) IT (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001256-20 Sponsor Protocol Number: ITI 101724 Start Date*: 2005-11-03
    Sponsor Name:GlaxoSmithKline Research and Development Ltd.
    Full Title: A randomized, double blind, double dummy, parallel group, placebo controlled study to evaluate the pharmacodynamic and pharmacokinetic response and safety and tolerability of SB424323 (250 mg, 375 ...
    Medical condition: Non-valvular Atrial Fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) EE (Completed) HU (Completed) DK (Completed) LV (Completed) IT (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-004522-16 Sponsor Protocol Number: DU176b-C-U301 Start Date*: 2009-05-20
    Sponsor Name:Daiichi Sankyo Pharma Development
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MULTI-CENTER, MULTI-NATIONAL STUDY FOR EVALUATION OF EFFICACY AND SAFETY OF DU-176B VERSUS WARFARIN IN SUBJECTS WITH ATRIAL FIBRIL...
    Medical condition: Reduction of Stroke and/or systemic embolic event (SEE) in subjects with atrial fibrillation (AF).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) SE (Completed) EE (Completed) FI (Completed) NL (Completed) PT (Completed) DK (Completed) ES (Completed) CZ (Completed) IT (Completed) BG (Completed) HU (Completed) SK (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002004-24 Sponsor Protocol Number: CV185-316 Start Date*: 2017-02-08
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillatio...
    Medical condition: Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    20.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    20.0 10042613 - Surgical and medical procedures 10065608 Percutaneous coronary intervention PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) BG (Completed) AT (Completed) BE (Completed) DK (Completed) NL (Completed) PL (Completed) PT (Completed) ES (Completed) CZ (Completed) DE (Completed) SE (Completed) SK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002263-96 Sponsor Protocol Number: 39486 Start Date*: 2012-07-11
    Sponsor Name:MUMC
    Full Title: dabigatran and rivaroxaban: prediction of anticoagulant effect
    Medical condition: non valvular atrial fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017176-25 Sponsor Protocol Number: WMLREC and BBC LREC Start Date*: 2010-09-08
    Sponsor Name:Sandwell and West Birmingham NHS Trust
    Full Title: Aspirin resistance and heart disease
    Medical condition: Index group 1 : coronary artery disease Index group 2: atrial fibrillation Control group 1: Diabetes/hypertension/hypercholesterolaemia Control group 2: Healthy subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-001898-90 Sponsor Protocol Number: Crijns01.12-02-026 Start Date*: 2012-06-25
    Sponsor Name:Maastricht University Medical Center
    Full Title: Effects of vernakalant and flecainide on atrial contractility in patients with atrial fibrillation
    Medical condition: Patients with paroxysmal or persistent atrial fibrillation (AF) reporting at the first heart aid.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003677-33 Sponsor Protocol Number: 7210 Start Date*: 2018-02-02
    Sponsor Name:Leiden University Medical Center
    Full Title: The Need for Titration or Monitoring of Direct Oral Anticoagulant Treatment: The MONDOAC and KIDOAC study
    Medical condition: patients who are diagnosed with atrial fibrillation or venous thrombosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002236-14 Sponsor Protocol Number: BI1160.206 Start Date*: 2015-10-28
    Sponsor Name:University Hospital Ulm
    Full Title: Phenprocoumon versus Dabigatran in subjects with atrial fibrillation and left atrial thrombus - a prospective, randomized, controlled, open-label one year follow-up pilot study
    Medical condition: left atrial thrombus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002404-41 Sponsor Protocol Number: MOSES Start Date*: 2022-08-26
    Sponsor Name:PD Dr. med. Mira Katan
    Full Title: Midregional proatrial natriuretic peptide to guide secondary stroke prevention: The MOSES-study
    Medical condition: Patients with ischemic stroke and elevated midregional proatrial natriuretic peptide (MRproANP) levels without known atrial fibrillation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004805-14 Sponsor Protocol Number: 2013-0001 Start Date*: 2014-08-14
    Sponsor Name:University Medical Center Groningen
    Full Title: Vitamin K antagonist (VKA)versus New Oral Anticoagulants (NOACs) in patients with currently well controlled VKA therapy for non-valvular atrial fibrillation: a pilot study
    Medical condition: non-valvular atrial fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-000994-39 Sponsor Protocol Number: BRD 06/2-D Start Date*: 2008-05-27
    Sponsor Name:Centre Hospitalier Universitaire de Nantes
    Full Title: Evaluation de l'intérêt d'un traitement par hydroquinidine pour la prise en charge des patients atteints d'un syndrome de Brugada à risque rythmique élevé et implantés d'un défibrillateur
    Medical condition: Patients with syndroma of Brugada who have an automatic implantable cardiac defibrillator
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059027 Brugada syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 12:39:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA